The DOI matches its Crossref record.
Drug Development Based on the Metals Hypothesis of Alzheimer's Disease
Abstract
The recent report of positive results from a Phase IIa clinical trial of PBT2, a novel drug that targets amyloid-beta-metal interactions, underscores the value of abnormal transition metal metabolism as a potential therapeutic target in Alzheimer's disease. The Metals Hypothesis of Alzheimer's disease is based upon observations of the precipitation of amyloid-beta by zinc and its radicalization by copper. Both metals are markedly enriched in plaques. The Hypothesis involves the perturbance of these endogenous brain metals, and it does not consider toxicological exposure part of pathogenesis. Recent descriptions of the release of ionic zinc and copper in the cortical glutamatergic synapse, modulating the response of the NMDA receptor, may explain the vulnerability of amyloid-beta to abnormal interaction with these metal ions in the synaptic region leading to aggregation and fostering toxicity. Increasingly sophisticated medicinal chemistry approaches are being tested which correct the abnormalities without causing systemic disturbance of these essential minerals. PBT2, clioquinol and related compounds are ionophores rather than chelators. PBT2 is a once per day, orally bioavailable, second generation 8-OH quinoline derivative of clioquinol. It has performed very satisfactorily in toxicology and Phase I clinical trials and is advancing as a disease-modifying candidate drug for Alzheimer's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Advances in metal-induced oxidative stress and human disease
Jomova, K., & Valko, M. (2011) · Toxicology · doi:10.1016/j.tox.2011.03.001 · Cited by 3,207
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
Copper homeostasis and cuproptosis in health and disease
Chen, L., Min, J., & Wang, F. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01229-y · Cited by 1,493
Metals, oxidative stress and neurodegenerative disorders
Jomova, K., Vondrakova, D., Lawson, M., & Valko, M. (2010) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-010-0563-x · Cited by 1,052
Zinc in the physiology and pathology of the CNS
Sensi, S. L., Paoletti, P., Bush, A. I., & Sekler, I. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2734 · Cited by 759
Self-citationExploration of the medical periodic table: towards new targets
Barry, N. P. E., & Sadler, P. J. (2013) · Chemical Communications · doi:10.1039/c3cc41143e · Cited by 717
Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics
Belaidi, A. A., & Bush, A. I. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13425 · Cited by 578
Self-citationButterfield, D. A., Swomley, A. M., & Sultana, R. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.5027 · Cited by 526
León, R., Garcia, A. G., & Marco‐Contelles, J. (2013) · Medicinal Research Reviews · doi:10.1002/med.20248 · Cited by 440
Metal dyshomeostasis and oxidative stress in Alzheimer’s disease
Greenough, M. A., Camakaris, J., & Bush, A. I. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2012.08.014 · Cited by 436
Self-citationPBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses
Faux, N. G., Ritchie, C. W., Gunn, A., Rembach, A., Tsatsanis, A., Bedo, J., Harrison, J., Lannfelt, L., Blennow, K., Zetterberg, H., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1390 · Cited by 405
Self-citationSmith, M. A., Zhu, X., Tabaton, M., Liu, G., McKeel, D. W., Cohen, M. L., Wang, X., Siedlak, S. L., Dwyer, B. E., Hayashi, T., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1239 · Cited by 401
Kell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361
Copper Dyshomeostasis in Neurodegenerative Diseases—Therapeutic Implications
Gromadzka, G., Tarnacka, B., Flaga, A., & Adamczyk, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239259 · Cited by 339
Importance of Iron Chelation in Free Radical-Induced Oxidative Stress and Human Disease
Jomova, K., & Valko, M. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211798072463 · Cited by 271
Fernández-Bachiller, M. I., Pérez, C., González-Muñoz, G. C., Conde, S., López, M. G., Villarroya, M., García, A. G., & Rodríguez-Franco, M. I. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100329q · Cited by 268
Methionine-35 of A β (1–42): Importance for Oxidative Stress in Alzheimer Disease
Butterfield, D. A., & Sultana, R. (2011) · Journal of Amino Acids · doi:10.4061/2011/198430 · Cited by 124
“An effective chelator clioquinol (CQ, 5-chloro-7iodoquinolin-8-ol), hydroxyquinoline antibiotic was found to be an effective high-affinity chelator in blocking the formation of hydrogen peroxide by Aβ [75, 80] and resulted”
BackgroundQiang, X., Sang, Z., Yuan, W., Li, Y., Liu, Q., Bai, P., Shi, Y., Ang, W., Tan, Z., & Deng, Y. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.02.045 · Cited by 113
“The abnormal accumulation of metals is closely associated with the formation of Ab plaques and neurofibrillary tangles [11].”
BackgroundA review of β-amyloid neuroimaging in Alzheimer's disease
Adlard, P. A., Tran, B. A., Finkelstein, D. I., Desmond, P. M., Johnston, L. A., Bush, A. I., & Egan, G. F. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00327 · Cited by 93
“Aβ aggregation may be a consequence of interactions with other factors such as the metals zinc and copper, which are dysregulated in the AD brain (Bush, 2008; Kawahara, 2010).”
BackgroundSelf-citationPuentes-Díaz, N., Chaparro, D., Morales-Morales, D., Flores-Gaspar, A., & Alí-Torres, J. (2023) · ACS Omega · doi:10.1021/acsomega.2c06939 · Cited by 67
Malek, R., Arribas, R. L., Palomino-Antolin, A., Totoson, P., Demougeot, C., Kobrlova, T., Soukup, O., Iriepa, I., Moraleda, I., Diez-Iriepa, D., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00937 · Cited by 45
A closer look at the mycobiome in Alzheimer’s disease: Fungal species, pathogenesis and transmission
Phuna, Z. X., & Madhavan, P. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15599 · Cited by 41
“Metal ion hypothesis The release of zinc and copper ions in the cortical glutamatergic synapse can alter the response of the Nmethyl-D-aspartate (NMDA) receptor, which makes the Aβ more prone to abnormal interaction with this metal ion in the synaptic region and subsequently result in Aβ aggregation and toxicity (Bush…”
BackgroundCopper neurotoxicity: Induction of cognitive dysfunction: A review
Feng, D., Zhao, Y., Li, W., Li, X., Wan, J., & Wang, F. (2023) · Medicine · doi:10.1097/md.0000000000036375 · Cited by 38
Mital, M., Zawisza, I. A., Wiloch, M. Z., Wawrzyniak, U. E., Kenche, V., Wróblewski, W., Bal, W., & Drew, S. C. (2016) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.6b00832 · Cited by 32
Metadata
- Authors
- Bush, A. I.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2008-10-07
- Volume
- 15
- Issue
- 2
- Pages
- 223-240
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1838272947
- Cited by
- 267
- References
- 0
- FWCI
- 12.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.